📣 VC round data is live. Check it out!
- Public Comps
- Guardant Health
Guardant Health Valuation Multiples
Discover Guardant Health's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Hologic, Exact Sciences, United Imaging, Labcorp and more.
Guardant Health Overview
About Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Founded
2011
HQ

Employees
2.5K
Website
Financials (LTM)
EV
$18B
Valuation Multiples
Start free trialGuardant Health Financials
Guardant Health reported last 12-month revenue of $1B and negative EBITDA of ($203M).
In the same LTM period, Guardant Health generated $727M in gross profit, ($203M) in EBITDA losses, and had net loss of ($387M).
Revenue (LTM)
Guardant Health P&L
In the most recent fiscal year, Guardant Health reported revenue of $982M and EBITDA of ($222M).
Guardant Health is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (23%), and net margin of (42%).
Financial data powered by Morningstar, Inc.
Guardant Health Stock Performance
Guardant Health has current market cap of $17B, and enterprise value of $18B.
Market Cap Evolution
Guardant Health's stock price is $129.18.
Guardant Health share price decreased by 0.5% in the last 30 days, and increased by 148.2% in the last year.
Guardant Health has an EPS (earnings per share) of $-3.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18B | $17B | -0.5% | -0.5% | 39.9% | 148.2% | $-3.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGuardant Health Valuation Multiples
Guardant Health trades at 15.8x EV/Revenue multiple, and (87.5x) EV/EBITDA.
EV / Revenue (LTM)
Guardant Health Financial Valuation Multiples
As of June 2, 2026, Guardant Health has market cap of $17B and EV of $18B.
Guardant Health has a P/E ratio of (44.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Guardant Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Guardant Health Margins & Growth Rates
Guardant Health grew revenue by 34% but EBITDA decreased by 21% in the last fiscal year.
In the most recent fiscal year, Guardant Health reported gross margin of 64%, EBITDA margin of (23%), and net margin of (42%).
Guardant Health Margins
Guardant Health Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Guardant Health Operational KPIs
Guardant Health's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Guardant Health's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guardant Health's Rule of X is 71% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Guardant Health Competitors
Guardant Health competitors include Hologic, Exact Sciences, United Imaging, Labcorp, Quest Diagnostics, Revvity, Pro Medicus, bioMérieux, Illumina and Qiagen.
Most Guardant Health public comparables operate across Medical Imaging & Diagnostics, Diagnostics & Genomics, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| - | - | - | - | |||
| 6.5x | 6.0x | 35.1x | 34.3x | |||
| 2.0x | 1.9x | 11.4x | 11.1x | |||
| 2.5x | 2.4x | 12.5x | 12.2x | |||
| 4.8x | 4.8x | 16.2x | 15.8x | |||
| 69.8x | 58.5x | 90.2x | 64.2x | |||
| 2.1x | 2.1x | 8.6x | 8.6x | |||
This data is available for Pro users. Sign up to see all Guardant Health competitors and their valuation data. Start Free Trial | ||||||
Guardant Health VC Funding History
Before going public, Guardant Health raised $550M in total equity funding, across 5 rounds.
Guardant Health Funding Rounds
Acquisitions by Guardant Health
Guardant Health has acquired 1 company to date.
Last acquisition by Guardant Health was on March 28th 2019. Guardant Health acquired Bellwether Bio for $30M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Guardant Health
| Description | Bellwether Bio is a biotechnology company developing cell-free DNA diagnostic technologies for oncology and other applications. Its platforms enable non-invasive liquid biopsies for early detection and monitoring. |
| HQ Country | |
| HQ City | Seattle, WA |
| Deal Date | 28 Mar 2019 |
| Valuation | $30M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Guardant Health acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Guardant Health
Guardant Health has invested in 1 company to date.
Latest investment by Guardant Health was on July 19th 2021. Guardant Health invested in Lunit in their $26M Series C round (EV/Revenue multiple available to Pro users).
Latest Investments by Guardant Health
| Description | Lunit Inc is a medical AI software company devoted to providing AI-powered total cancer care. Its products comprise of Lunit INSIGHT CXR, AI solution for Chest x-ray; Lunit INSIGHT MMG, AI solution for Mammography; Lunit SCOPE IO, AI-Powered Biomarker for Immuno-Oncology; and Lunit SCOPE PD-L1, AI Solution for PD-L1 Expression. |
| HQ Country | |
| HQ City | - |
| Deal Date | 19 Jul 2021 |
| Round | Series C |
| Raised | $26M |
| Investors | Guardant Health |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Guardant Health investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Guardant Health
| When was Guardant Health founded? | Guardant Health was founded in 2011. |
| Where is Guardant Health headquartered? | Guardant Health is headquartered in United States. |
| How many employees does Guardant Health have? | As of today, Guardant Health has over 2K employees. |
| Who is the CEO of Guardant Health? | Guardant Health's CEO is Helmy Eltoukhy. |
| Is Guardant Health publicly listed? | Yes, Guardant Health is a public company listed on Nasdaq. |
| What is the stock symbol of Guardant Health? | Guardant Health trades under GH ticker. |
| When did Guardant Health go public? | Guardant Health went public in 2018. |
| Who are competitors of Guardant Health? | Guardant Health main competitors include Hologic, Exact Sciences, United Imaging, Labcorp, Quest Diagnostics, Revvity, Pro Medicus, bioMérieux, Illumina, Qiagen. |
| What is the current market cap of Guardant Health? | Guardant Health's current market cap is $17B. |
| What is the current revenue of Guardant Health? | Guardant Health's last 12 months revenue is $1B. |
| What is the current revenue growth of Guardant Health? | Guardant Health revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Guardant Health? | Current revenue multiple of Guardant Health is 15.8x. |
| Is Guardant Health profitable? | No, Guardant Health is not profitable. |
| What is the current EBITDA of Guardant Health? | Guardant Health has negative EBITDA and is not profitable. |
| What is Guardant Health's EBITDA margin? | Guardant Health's last 12 months EBITDA margin is (18%). |
| What is the current EV/EBITDA multiple of Guardant Health? | Current EBITDA multiple of Guardant Health is (87.5x). |
| What is the current FCF of Guardant Health? | Guardant Health's last 12 months FCF is ($255M). |
| What is Guardant Health's FCF margin? | Guardant Health's last 12 months FCF margin is (23%). |
| What is the current EV/FCF multiple of Guardant Health? | Current FCF multiple of Guardant Health is (69.5x). |
| How many companies Guardant Health has acquired to date? | As of June 2026, Guardant Health has acquired 1 company. |
| What was the largest acquisition by Guardant Health? | $30M acquisition of Bellwether Bio on 28th March 2019 was the largest M&A Guardant Health has done to date. |
| What companies Guardant Health acquired? | Guardant Health acquired Bellwether Bio. |
| In how many companies Guardant Health has invested to date? | As of June 2026, Guardant Health has invested in 1 company. |
| What was the last Guardant Health investment? | On 19th July 2021 Guardant Health invested in Lunit, participating in a $26M Series C round. |
| In what companies Guardant Health invested in? | Guardant Health invested in Lunit. |
See public comps similar to Guardant Health
Lists including Guardant Health
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

